Estrogen replacement raises rat CRP without evidence of complement activation

Endocrine Research

Volumn 31, Issue 2, 2005, Pages 121-132

  Yang, S X ^a   Zhu, Q ^a   Ma, X M ^a   Sasso, D ^a   Prestwood, K ^a   Kuchel, G A ^a   Diaz Padilla, N ^b   Hack, C E ^b,c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C reactive protein; Complement activation; Estrogen; Hormone replacement therapy; Inflammation

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; CARRIER PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C4B; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; LIVER; OVARIECTOMY; RATS; RATS, INBRED F344;

EID: 28744451493     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.1080/07435800500229268     Document Type: Article

References (48)

1. Wenger NK. Coronary heart disease: an older woman's major health risk. BMJ 1997; 315(7115):1085-1090.
2. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23(1):90-119.
3. Sites CK, Toth MJ, Cushman M, L'Hommedieu GD, Tchernof A, Tracy RP, Poehlman ET. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002; 77(1):128-135.
4. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T, Aono T. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 2001; 184(3):309-314.
5. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Murata K, Yasui T, Yamano S, Aono T. Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. Gynecol Obstet Invest 2001; 52(2):82-88.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342(12):836-843.
7. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17(6):1121-1127.
8. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women's health initiative observational study. JAMA 2002; 288(8):980-987.
9. Miller AP, Chen YF, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003; 42(4):657-663.
10. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP.. Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 1999; 100(7):717-722.
11. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100(7):713-716.
12. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6. 8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288(1):49-57.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288(3):321-333.
14. Nunomura W. C-reactive protein in rat: in development, pregnancy and effect of sex hormones. Comp Biochem Physiol A 1990; 96(4):489-493.
15. Nunomura W, Takakuwa Y, Higashi T. Changes in serum concentration and mRNA level of rat C-reactive protein. Biochim Biophys Acta 1994; 1227(1-2):74-78.
16. Szalai AJ. The biological functions of C-reactive protein. Vascul Pharmacol 2002; 39(3):105-107.
17. Diaz PN, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE. Rat C-reactive protein activates the autologous complement system. Immunology 2003; 109(4):564-571.
18. Legan SJ, Allyn Coon G, Karsch FJ. A role of estrogen as initiator of daily LH surges in the ovariectomized rat. Endocrinology 1975; 96(1):50-56.
19. Daniel JM, Roberts SL, Dohanich GP. Effects of ovarian hormones and environment on radial maze and water maze performance of female rats. Physiol Behav 1999; 66(1):11-20.
20. Bos IG, Van Mierlo GJ, Bleeker WK, Rigter GM, te VH, Dickneite G, Hack CE. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int Immunopharmacol 2001; 1(8):1583-1595.
21. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158(3):1039-1051.
22. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41(8):1358-1363.
23. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002; 17(11):2080-2086.
24. Volanakis JE. Complement activation by C-reactive protein complexes. Ann N Y Acad Sci 1982; 389:235-250.
25. Manolov DE, Koenig W, Hombach V, Torzewski J. C-reactive protein and atherosclerosis. Is there a causal link? Histol Histopathol 2003; 18(4):1189-1193.
26. De Beer FC Baltz ML, Munn EA, Feinstein A, Taylor J, Bruton C, Clamp JR, Pepys MB. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 1982; 45(1):55-70.
27. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190(12):1733-1740.
28. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996; 157(1):473-479.
29. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192(9):1353-1364.
30. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, Meijer CJ, Hack CE. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95(1):97-103.
31. Herrington DM, Brosnihan KB, Pusser BE, Seely EW, Ridker PM, Rifai N, MacLean DB. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86(9):4216-4222.
32. Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA, Fini M, Mercuro G, Rosano GM. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107(25):3165-3169.
33. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000; 85(3):1340-1344.
34. Lacut K, Oger E, Le Gal G, Blouch MT, Abgrall JF, Kerlan V, Scarabin PY, Mottier D. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003; 90(1):124-131.
35. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88(7):825-828.
36. Burger D, Dayer JM. Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci 2002; 966:464-473.
37. Weinhold B, Bader A, Poli V, Ruther U. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 1997; 325(Pt 3):617-621.
38. Gabay C, Kushner I.. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6):448-454.
39. Bruun JM, Nielsen CB, Pedersen SB, Flyvbjerg A, Richelsen B. Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. Horm Metab Res 2003; 35(3):142-146.
40. Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165(2):301-307.
41. Sattar N, Perera M, Small M, Lumsden MA. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 1999; 354(9177):487-488.
42. Kawano H, Yasue H, Hirai N, Yoshida T, Fukushima H, Miyamoto S, Kojima S, Hokamaki J, Nakamura H, Yodoi J, Ogawa H. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int J Clin Pharmacol Ther 2003; 41(8):346-353.
43. Nagae Y, Miyamoto M, Miyamoto H. Effect of estrogen replacement on liver function in ovariectomized rats. J Toxicol Sci 1991; 16(3):87-100.
44. Middleton RB, Linder MC. Synthesis and turnover of ceruloplasmin in rats treated with 17 beta-estradiol. Arch Biochem Biophys 1993; 302(2):362-368.
45. Koh KK.. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55(4):714-726.
46. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24(3):571-576.
47. Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci 2004; 59(8):827-832.
48. Koh KK, Shin MS, Sakuma I, Ahn JY, Jin DK, Kim HS, Kim DS, Han SH, Chung WJ, Shin EK.. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24(8):1516-1521.